Gram-negative bacterial infections

Research priorities, accomplishments, and future directions of the Antibacterial Resistance Leadership Group

Yohei Doi, Robert A. Bonomo, David C. Hooper, Keith S. Kaye, James R. Johnson, Cornelius J. Clancy, Joshua T. Thaden, Martin E. Stryjewski, David Van Duin

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Antimicrobial resistance in pathogenic gram-negative bacteria is one of the most pressing challenges in the field of infectious diseases and is one of 4 key areas of unmet medical need identified by the Antibacterial Resistance Leadership Group (ARLG). The mission of the Gram-Negative Committee is to advance our knowledge of these challenging infections and implement studies to improve patient outcomes. Studies have fallen primarily into 2 broad categories: prospective cohort studies and interventional trials. Among the observational studies, CRACKLE (Consortium on Resistance Against Carbapenems in Klebsiella pneumoniae and Other Enterobacteriaceae) has contributed seminal multicenter data describing risk factors and clinical outcomes of carbapenem-resistant Enterobacteriaceae (CRE) in sentinel US hospitals. Building on this success, CRACKLE II will expand the network to hospitals across the United States and Colombia. Similar protocols have been proposed to include Acinetobacter baumannii and Pseudomonas aeruginosa (SNAP and POP studies). In addition, the CREST study (Carbapenem-Resistant Enterobacteriaceae in Solid Organ Transplant Patients) has provided pivotal data on extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae and CRE carriage among solid organ transplant recipients to inform management of this vulnerable patient population. Two clinical trials to define novel ways of using an existing antibiotic, fosfomycin, to treat ESBL-producing Enterobacteriaceae (one that has completed enrollment and the other in late protocol development) will determine the clinical efficacy of fosfomycin as step-down oral therapy to treat complicated urinary tract infections. Additional clinical studies and trials using immunotherapeutic or newly approved agents are also in the planning stage, with the main goals of generating actionable data that will inform clinical decision making and facilitate development of new treatment options for highly resistant gram-negative bacterial infections.

Original languageEnglish
Pages (from-to)S30-S35
JournalClinical Infectious Diseases
Volume64
DOIs
Publication statusPublished - 01-01-2017
Externally publishedYes

Fingerprint

Gram-Negative Bacterial Infections
Enterobacteriaceae
Carbapenems
Research
Fosfomycin
Clinical Trials
Transplants
Acinetobacter baumannii
Colombia
Klebsiella pneumoniae
Vulnerable Populations
Gram-Negative Bacteria
Urinary Tract Infections
Pseudomonas aeruginosa
Observational Studies
Communicable Diseases
Direction compound
Cohort Studies
Prospective Studies
Anti-Bacterial Agents

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Doi, Yohei ; Bonomo, Robert A. ; Hooper, David C. ; Kaye, Keith S. ; Johnson, James R. ; Clancy, Cornelius J. ; Thaden, Joshua T. ; Stryjewski, Martin E. ; Van Duin, David. / Gram-negative bacterial infections : Research priorities, accomplishments, and future directions of the Antibacterial Resistance Leadership Group. In: Clinical Infectious Diseases. 2017 ; Vol. 64. pp. S30-S35.
@article{a8b71275f1444d0b9511c9d956daa2ee,
title = "Gram-negative bacterial infections: Research priorities, accomplishments, and future directions of the Antibacterial Resistance Leadership Group",
abstract = "Antimicrobial resistance in pathogenic gram-negative bacteria is one of the most pressing challenges in the field of infectious diseases and is one of 4 key areas of unmet medical need identified by the Antibacterial Resistance Leadership Group (ARLG). The mission of the Gram-Negative Committee is to advance our knowledge of these challenging infections and implement studies to improve patient outcomes. Studies have fallen primarily into 2 broad categories: prospective cohort studies and interventional trials. Among the observational studies, CRACKLE (Consortium on Resistance Against Carbapenems in Klebsiella pneumoniae and Other Enterobacteriaceae) has contributed seminal multicenter data describing risk factors and clinical outcomes of carbapenem-resistant Enterobacteriaceae (CRE) in sentinel US hospitals. Building on this success, CRACKLE II will expand the network to hospitals across the United States and Colombia. Similar protocols have been proposed to include Acinetobacter baumannii and Pseudomonas aeruginosa (SNAP and POP studies). In addition, the CREST study (Carbapenem-Resistant Enterobacteriaceae in Solid Organ Transplant Patients) has provided pivotal data on extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae and CRE carriage among solid organ transplant recipients to inform management of this vulnerable patient population. Two clinical trials to define novel ways of using an existing antibiotic, fosfomycin, to treat ESBL-producing Enterobacteriaceae (one that has completed enrollment and the other in late protocol development) will determine the clinical efficacy of fosfomycin as step-down oral therapy to treat complicated urinary tract infections. Additional clinical studies and trials using immunotherapeutic or newly approved agents are also in the planning stage, with the main goals of generating actionable data that will inform clinical decision making and facilitate development of new treatment options for highly resistant gram-negative bacterial infections.",
author = "Yohei Doi and Bonomo, {Robert A.} and Hooper, {David C.} and Kaye, {Keith S.} and Johnson, {James R.} and Clancy, {Cornelius J.} and Thaden, {Joshua T.} and Stryjewski, {Martin E.} and {Van Duin}, David",
year = "2017",
month = "1",
day = "1",
doi = "10.1093/cid/ciw829",
language = "English",
volume = "64",
pages = "S30--S35",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",

}

Gram-negative bacterial infections : Research priorities, accomplishments, and future directions of the Antibacterial Resistance Leadership Group. / Doi, Yohei; Bonomo, Robert A.; Hooper, David C.; Kaye, Keith S.; Johnson, James R.; Clancy, Cornelius J.; Thaden, Joshua T.; Stryjewski, Martin E.; Van Duin, David.

In: Clinical Infectious Diseases, Vol. 64, 01.01.2017, p. S30-S35.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Gram-negative bacterial infections

T2 - Research priorities, accomplishments, and future directions of the Antibacterial Resistance Leadership Group

AU - Doi, Yohei

AU - Bonomo, Robert A.

AU - Hooper, David C.

AU - Kaye, Keith S.

AU - Johnson, James R.

AU - Clancy, Cornelius J.

AU - Thaden, Joshua T.

AU - Stryjewski, Martin E.

AU - Van Duin, David

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Antimicrobial resistance in pathogenic gram-negative bacteria is one of the most pressing challenges in the field of infectious diseases and is one of 4 key areas of unmet medical need identified by the Antibacterial Resistance Leadership Group (ARLG). The mission of the Gram-Negative Committee is to advance our knowledge of these challenging infections and implement studies to improve patient outcomes. Studies have fallen primarily into 2 broad categories: prospective cohort studies and interventional trials. Among the observational studies, CRACKLE (Consortium on Resistance Against Carbapenems in Klebsiella pneumoniae and Other Enterobacteriaceae) has contributed seminal multicenter data describing risk factors and clinical outcomes of carbapenem-resistant Enterobacteriaceae (CRE) in sentinel US hospitals. Building on this success, CRACKLE II will expand the network to hospitals across the United States and Colombia. Similar protocols have been proposed to include Acinetobacter baumannii and Pseudomonas aeruginosa (SNAP and POP studies). In addition, the CREST study (Carbapenem-Resistant Enterobacteriaceae in Solid Organ Transplant Patients) has provided pivotal data on extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae and CRE carriage among solid organ transplant recipients to inform management of this vulnerable patient population. Two clinical trials to define novel ways of using an existing antibiotic, fosfomycin, to treat ESBL-producing Enterobacteriaceae (one that has completed enrollment and the other in late protocol development) will determine the clinical efficacy of fosfomycin as step-down oral therapy to treat complicated urinary tract infections. Additional clinical studies and trials using immunotherapeutic or newly approved agents are also in the planning stage, with the main goals of generating actionable data that will inform clinical decision making and facilitate development of new treatment options for highly resistant gram-negative bacterial infections.

AB - Antimicrobial resistance in pathogenic gram-negative bacteria is one of the most pressing challenges in the field of infectious diseases and is one of 4 key areas of unmet medical need identified by the Antibacterial Resistance Leadership Group (ARLG). The mission of the Gram-Negative Committee is to advance our knowledge of these challenging infections and implement studies to improve patient outcomes. Studies have fallen primarily into 2 broad categories: prospective cohort studies and interventional trials. Among the observational studies, CRACKLE (Consortium on Resistance Against Carbapenems in Klebsiella pneumoniae and Other Enterobacteriaceae) has contributed seminal multicenter data describing risk factors and clinical outcomes of carbapenem-resistant Enterobacteriaceae (CRE) in sentinel US hospitals. Building on this success, CRACKLE II will expand the network to hospitals across the United States and Colombia. Similar protocols have been proposed to include Acinetobacter baumannii and Pseudomonas aeruginosa (SNAP and POP studies). In addition, the CREST study (Carbapenem-Resistant Enterobacteriaceae in Solid Organ Transplant Patients) has provided pivotal data on extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae and CRE carriage among solid organ transplant recipients to inform management of this vulnerable patient population. Two clinical trials to define novel ways of using an existing antibiotic, fosfomycin, to treat ESBL-producing Enterobacteriaceae (one that has completed enrollment and the other in late protocol development) will determine the clinical efficacy of fosfomycin as step-down oral therapy to treat complicated urinary tract infections. Additional clinical studies and trials using immunotherapeutic or newly approved agents are also in the planning stage, with the main goals of generating actionable data that will inform clinical decision making and facilitate development of new treatment options for highly resistant gram-negative bacterial infections.

UR - http://www.scopus.com/inward/record.url?scp=85026371092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026371092&partnerID=8YFLogxK

U2 - 10.1093/cid/ciw829

DO - 10.1093/cid/ciw829

M3 - Article

VL - 64

SP - S30-S35

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

ER -